Apr, 2025

Global
News / Press Releases
Notice Regarding Change in fair value of contingent consideration and Differences Between Consolidated Financial Forecasts and Actual Results for the Fiscal Year Ended March 31, 2025
TOKYO, April 25, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked Change in fair value of contingent consideration as other income in the fourth quarter of fiscal year ended March 31,2025 and that there are differences between the financial forecasts (Full basis), which were reported on January 24, 2025, and the actual results for...
Read More
Global
News / IR
Posted Financial Results for FY2024
Read More
Global
News / Stories
The Future of Drug Discovery: Integrating Human, AI and Robotics
Read More
Global
News / Stories
Agile Mindset: Enhancing Patient Access and Engagement
Read More
Global
News / Press Releases
Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research
TOKYO, April 2, 2025 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Japanese Foundation for Cancer Research (Chairman: Toshio Asano, Ph.D., “JFCR”) today announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research. The collaboration leverages Astellas’ unique scientific, translational and clinical...
Read More

Apr, 2025

Global
News / Press Releases
Notice Regarding Change in fair value of contingent consideration and Differences Between Consolidated Financial Forecasts and Actual Results for the Fiscal Year Ended March 31, 2025
TOKYO, April 25, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked Change in fair value of contingent consideration as other income in the fourth quarter of fiscal year ended March 31,2025 and that there are differences between the financial forecasts (Full basis), which were reported on January 24, 2025, and the actual results for...
Read More
Global
News / Press Releases
Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research
TOKYO, April 2, 2025 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Japanese Foundation for Cancer Research (Chairman: Toshio Asano, Ph.D., “JFCR”) today announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research. The collaboration leverages Astellas’ unique scientific, translational and clinical...
Read More

Mar, 2025

Global
News / Press Releases
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
TOKYO, March 6, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, “YASKAWA”) signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot "Maholo." In addition, the joint venture will...
Read More

Feb, 2025

Global
News / Press Releases
U.S. FDA Approves Expanded Label for Astellas’ IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
TOKYO, February 13, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY is now...
Read More
Global
News / Press Releases
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/muC At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom